Skip to main content Skip to footer
Algernon Health Inc
  • Home
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical & Scientific Advisors
  • Alzheimer’s
    • Overview
    • AD Clinics
    • Markets
    • Resources
  • Pipeline
    • Overview
    • NP-251 (Repirinast)
    • AP-188 (DMT)
  • Companies
    • Algernon NeuroScience
  • News & Media
    • News Releases
    • IR Calendar
    • Presentations
    • Videos/Articles
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEDAR
    • Governance
  • Contact

We are currently in the process of updating our web site to reflect the announced plans to change our company name from Algernon Pharmaceuticals to Algernon Health. Please visit again soon as these changes continue to take effect across the entire web site.

News Releases

Mar 02, 2021 10:18pm EST

Algernon Pharmaceuticals Announces Private Placement

Mar 01, 2021 8:00am EST

Algernon Pharmaceuticals to Conduct Phase 1 DMT Stroke Program Study with Hammersmith Medicines Research (UK)

Mar 01, 2021 7:00am EST

Algernon Pharmaceuticals Appoints VP Research & Operations and Chief Medical Officer

Feb 25, 2021 7:00am EST

Algernon Pharmaceuticals CEO to Speak at the Psychedelic Capital Virtual Investment Conference

Feb 19, 2021 8:00am EST

Algernon Pharmaceuticals Awards DMT Manufacturing Contract to Dalton Pharma for Stroke Program

Feb 17, 2021 7:47am EST

Algernon Pharmaceuticals Provides Update on COVID-19 Phase 2b Final Study Data

Feb 10, 2021 7:00am EST

Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

Feb 08, 2021 8:05am EST

Algernon Pharmaceuticals Signs Agreement with Charles River Laboratories for DMT Preclinical Studies

Feb 03, 2021 8:00am EST

Algernon CEO and CSO to Discuss New DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD

Feb 01, 2021 7:30am EST

Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT “The Spirit Molecule”

  • Previous Pagearrow_back
  • Page 1…
  • …
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • …
  • …Page 23
  • Next Pagearrow_forward
rss_feed News RSS
  • Visit us on Facebook

    Facebook

  • Visit us on Twitter

    Twitter

  • Visit us on LinkedIn

    LinkedIn

  • Email Alerts
©2025 Algernon Health Inc. All Rights Reserved.
Privacy Policy Sitemap